Glycerol Monolaurate and Dodecylglycerol Effects on Staphylococcus aureus and Toxic Shock Syndrome Toxin-1 In Vitro and In Vivo by Lin, Ying-Chi et al.
Glycerol Monolaurate and Dodecylglycerol Effects on
Staphylococcus aureus and Toxic Shock Syndrome
Toxin-1 In Vitro and In Vivo
Ying-Chi Lin
1, Patrick M. Schlievert
2, Michele J. Anderson
1, Christina L. Fair
1, Matthew M. Schaefers
1,
Ramaiah Muthyala
1,3, Marnie L. Peterson
1,2*
1Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States of America, 2Department
of Microbiology, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America, 3Center for Orphan Drug Research, University of Minnesota,
Minneapolis, Minnesota, United States of America
Abstract
Background: Glycerol monolaurate (GML), a 12 carbon fatty acid monoester, inhibits Staphylococcus aureus growth and
exotoxin production, but is degraded by S. aureus lipase. Therefore, dodecylglycerol (DDG), a 12 carbon fatty acid
monoether, was compared in vitro and in vivo to GML for its effects on S. aureus growth, exotoxin production, and stability.
Methodology/Principal Findings: Antimicrobial effects of GML and DDG (0 to 500 mg/ml) on 54 clinical isolates of S. aureus,
includingpulsed-field gel electrophoresis(PFGE) types USA200, USA300, and USA400, were determined in vitro. A rabbit Wiffle
ball infection model assessed GML and DDG (1 mg/ml instilled into the Wiffle ball every other day) effects on S. aureus (MN8)
growth (inoculum 3610
8 CFU/ml), toxic shock syndrome toxin-1 (TSST-1) production, tumor necrosis factor-a (TNF-a)
concentrations and mortality over 7 days. DDG (50 and 100 mg/ml) inhibited S. aureus growth in vitro more effectively than
GML(p,0.01) and wasstableto lipasedegradation. UnlikeGML, DDGinhibitionofTSST-1wasdependent onS.aureusgrowth.
GML-treated(4of5;80%)andDDG-treatedrabbits(2of5;40%)survivedafter7days. Controlrabbits(5of5;100%)succumbed
by day 4. GML suppressed TNF-a at the infection site on day 7; however, DDG did not (,10 ng/ml versus 80 ng/ml,
respectively).
Conclusions/Significance: These data suggest that DDG was stable to S. aureus lipase and inhibited S. aureus growth at lower
concentrations than GML in vitro. However, in vivo GML was more effective than DDG by reducing mortality, and suppressing
TNF-a, S. aureus growth and exotoxin production, which may reduce toxic shock syndrome. GML is proposed as a more
effective anti-staphylococcal topical anti-infective candidate than DDG, despite its potential degradation by S. aureus lipase.
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Introduction
Staphylococcus aureus is an important cause of skin and mucosal
infections both in hospital and community settings [1,2]. Approxi-
mately 20% of the U.S. population is persistently colonized by S. aureus
in the nose, and 30% are intermittently colonized [1]. People colonized
with S. aureus are at higher risk of becoming infected by the organism,
especially when host defenses are breached, for example, postsurgical
wounds, catheter insertions, or burn wounds. People suffering from
atopic dermatitis are more likely to be colonized and infected by S.
aureus than the general population. Superantigens produced by S. aureus
are known factors that enhance skin inflammation in atopic dermatitis
and may be responsible for steroid resistant T cell responses [3].
Superantigens,especially toxic shock syndrometoxin 1 (TSST-1),
are also responsible for systemic exotoxemias such as toxic shock
syndrome (TSS), an acute onset and potentially life-threatening
illness. Clinical manifestations of TSS include fever, hypotension,
rash, desquamation, and multi-organ failure. These symptoms are
the result of overwhelming cytokine production systemically due to
abnormal cross-linkage between T cells and macrophages by
superantigens. The most recognized cases of TSS are associated
with tampon usage in menstruating women; however, TSS is also
associated with S. aureus infections at surgical or skin infection sites
[2,4]. Bacterial contamination of wound dressings, in particular
occlusive dressings, have been suggested as the source of infection in
some TSS cases [5].
Based on pulsed-field gel electrophoresis (PFGE), S. aureus
strains can be grouped into several clonal types. In the United
States, USA200 PFGE type were the most common methicillin
susceptible S. aureus (MSSA) isolates recovered from national nasal
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7499colonization studies [6]. USA200 clonal type, which is genetically
similar to the epidemic hospital strain EMRSA16 in the United
Kingdom, is also the major clonal type associated with TSS,
presumably due to the high prevalence of these isolates to possess
tst (the gene for TSST-1). USA300 and USA400 clonal types have
been associated recently with necrotizing pneumonia and
necrotizing fasciitis in community settings [7]. Methicillin resistant
S. aureus (MRSA) USA300 has emerged as one of the major causes
of invasive staphylococcal infections in both community and
hospital settings [7,8].
Protein-synthesis inhibitors, such as clindamycin and linezolid
inhibit TSST-1 production at sub-growth inhibitory concentra-
tions, and the suppression is associated with improved clinical
responses in patients with TSS [9–11]. However, these antibiotics
are often recommended for treating antibiotic resistant S. aureus
infections, and not for TSS prophylaxis. On the other hand, b-
lactam antibiotics induce or increase TSST-1 production, which
may increase the risk of TSS in patients with severe staphylococcal
infections, especially by MRSA [12]. Given that most S. aureus
infections are initiated at mucosal and skin sites, topical anti-
staphylococcal agents, that can be incorporated into wound
dressings, disposable medical devices, or tampons to inhibit toxin
production and/or S. aureus growth and thus prevent S. aureus
infections or TSS, would have clinical value.
Glycerol monolaurate (GML) (2,3-dihydroxypropyl dodecano-
ate) is a lauric acid glycerol ester commonly used in the food and
cosmetic industries as an emulsifier and preservative and is
generally recognized as safe (GRAS) by the Food and Drug
Administration for topical use at doses up to 100 mg/ml. GML
interferes with membrane signal transduction and thereby inhibits
the growth of S. aureus, blocks the induction of b-lactamase, and
delays the production of S. aureus exoproteins, such as TSST-1 and
a-toxin [13–15]. GML also reduces the production of proin-
flammatory cytokines and chemokines by mammalian cells in
response to S. aureus and purified TSST-1 (100 mg/ml), and
prevents lethality in rabbits challenged vaginally with TSST-1
[16,17]. Given these properties, GML has been tested as a tampon
additive and reduces staphylococcal exotoxin production in vivo
[18]. In addition, GML (5% gel) has been demonstrated recently
to prevent vaginal SIV transmission in monkeys by inhibiting
innate inflammatory responses [19]. The compound, however, is
not stable in the presence of S. aureus and can be hydrolyzed by S.
aureus esterase (lipase) into glycerol and lauric acid [13,15]. To
overcome the limitation of inactivation, compounds with ether
linkage have been suggested as potential alternatives to GML.
Many of these ether compounds inhibit TSST-1 production in
addition to S. aureus growth, and they are more stable than ester
compounds (such as GML) to chemical and enzymatic hydrolysis
[20,21]. 1-O-Dodecyl-rac-glycerol (DDG) (3-(dodecyloxy)pro-
pane-1,2-diol) is the corresponding alkylglycerol ether to GML.
DDG inhibits the growth of Enterococcus faecium and Streptococcus
mutans primarily by stimulating autolysin activity and interfering
with cell wall synthesis [21–25]. DDG simultaneously inhibits S.
aureus growth and TSST-1 production, but the mechanisms of
action has not been characterized [20].
Given the structural similarity of GML and DDG and its
supposed stability to lipase degradation over GML, DDG was
hypothesized to be more potent than GML at inhibiting S. aureus
growth and TSST-1 production, and therefore a better anti-
staphylococcal agent candidate than GML. Our goal was to
compare the efficacy of these two compounds on S. aureus growth,
and TSST-1 production in vitro and in vivo. We also studied in
vivo the interactions between host innate immune responses and
the compounds during S. aureus infection.
Results
Stability against S. aureus enzymes
GML- and DDG-containing agarose slides were exposed to S.
aureus overnight cultures to determine the stability of the
compounds to lipase contained in the culture supernates. A clear
zone was observed on the GML 500 mg/ml agarose slide, but not
the DDG 500 mg/ml slide (Fig. 1). The solubility limit of GML in
aqueous solutions at 37uC is approximately 100 mg/ml, and thus
the zone of clearance, reflecting GML degradation by lipase, can
be observed in the presence of a turbid background. The
observation indicated that DDG was resistant to degradation by
S. aureus MN8 lipase, while GML was not resistant to lipase.
In vitro growth inhibition
The differences in susceptibility to GML and DDG among S.
aureus strains were evaluated broadly using a large collection of
clinically relevant isolates (MSSA USA200, MRSA USA200,
MRSA USA300, MSSA USA400, MRSA USA400, vaginal
isolates from healthy women, and isolates from persons with
atopic dermatitis). Growth inhibitory effects of GML (50, 100, and
500 mg/ml) and DDG (25, 50, and 100 mg/ml) were examined at
18 h. In general, GML was bacteriostatic at concentrations of
50 mg/ml and 100 mg/ml, and was bactericidal (3 log decrease in
CFU/ml from the starting inoculum of 1610
7 CFU/ml) at the
concentration of 500 mg/ml (Fig. 2). On the other hand, DDG had
a bacteriostatic effect on most strain categories at the concentra-
tion of 25 mg/ml (one dilution lower than GML). As the
concentrations of DDG increased from 25 to 50 and 100 mg/ml,
bacterial densities decreased an additional 1–2 log CFU/ml
(Fig. 3). Overall, DDG was consistently more effective in
Figure 1. Stability of the compounds to Staphylococcus aureus (MN8) lipase. (A) Glycerol monolaurate (GML). (B) Dodecylglycerol (DDG).
Clear zone indicates that the compound was degraded. Arrow denotes of the radius of the clear zone on the slide.
doi:10.1371/journal.pone.0007499.g001
Monoester/Ether Kill S. aureus
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7499Figure 2. Glycerol monolaurate (GML) inhibition of Staphylococcus aureus. GML concentrations 50, 100, and 500 mg/ml were tested versus S.
aureus isolates from different PFGE types, USA400 MRSA (A), USA400 MSSA (B), USA300 MRSA (C), USA200 MRSA (D), USA200 MSSA (E), atopic
dermatitis strains (F), vaginal strains from healthy women (G), for 18 h at 37uC with shaking. The dashed line indicates the starting inocula. Each
square (&) indicates one isolate. The bars represent the mean6SEM of bacterial density in the group.
doi:10.1371/journal.pone.0007499.g002
Monoester/Ether Kill S. aureus
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7499Figure 3. Dodecylglycerol (DDG) inhibition of Staphylococcus aureus. DDG concentrations 25, 50, and 100 mg/ml were tested versus S. aureus
isolates from different PFGE types, USA400 MRSA (A), USA400 MSSA (B), USA300 MRSA (C), USA200 MRSA (D), USA200 MSSA (E), atopic dermatitis
strains (F), vaginal strains from healthy women (G), for 18 h at 37uC with shaking. The dashed line indicates the starting inocula. Each triangle (m)
indicates one isolate. The bars represent the mean6SEM of bacterial density in the group.
doi:10.1371/journal.pone.0007499.g003
Monoester/Ether Kill S. aureus
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including vaginal and atopic dermatitis strains, than GML at
concentrations of 50 and 100 mg/ml (p,0.01 for comparisons of
GML and DDG against all 54 strains at both concentrations).
There was no significant difference between MSSA and MRSA in
response to GML (p=0.79 and 0.12 for GML 50 and 100 mg/ml,
respectively); However, MRSA apear to be more susceptible to
DDG than MSSA at the concentrations 50 and 100 mg/ml
(p=0.01 and p,0.01, respectively). Some clonal variability was
noted among strains, where USA400 (MSSA and MRSA) strains
were relatively more resistant to DDG and the high dose of GML
(500 mg/ml) than other clonal types (USA300 and USA200)
tested. Community-associated MRSA USA300 strains were the
most susceptible clonal type to DDG.
In vitro TSST-1 suppression
To evaluate toxin inhibitory effects of the compounds at sub-
growth-inhibition concentrations, S. aureus MN8 was tested for
growth inhibition and the corresponding TSST-1 production by
GML (25 and 50 mg/ml) and DDG (5, 15, and 25 mg/ml) at 6 and
24 h. GML (25 and 50 mg/ml) inhibited bacterial growth at 6 h,
however, this bacteriostatic effect was no longer seen by 24 h
(Fig. 4A). TSST-1 level was significantly reduced by GML at 25
and 50 mg/ml at 6 h (.99% reduction), and this effect persisted
through 24 h (49% and 78% reduction, respectively) (Fig. 4B).
DDG (5 mg/ml) did not inhibit the growth of MN8, and did not
inhibit TSST-1 production (Fig. 4C). However, DDG (15 mg/ml)
inhibited the growth of MN8 at 6 h but not 24 h, and TSST-1
production was inhibited by .99% at 6 h and 61% at 24 h
Figure 4. Effects of GML and DDG on Staphylococcus aureus Toxic Shock Syndrome Toxin-1 (TSST-1) production. (A) S. aureus MN8 was
exposed to GML 0, 25 and 50 mg/ml for 6 and 24 h, and bacterial densities at 6 and 24 h were determined by plate counts. (B) The corresponding
concentrations of TSST-1 of the above GML experiment. (C) S. aureus MN8 was exposed to DDG 0, 5, 15, and 25 mg/ml for 6 and 24 h. (D) The
corresponding concentrations of TSST-1 from above DDG experiments. TSST-1 concentrations are presented as percent of the TSST-1 concentrations
in 24 h control samples. Results are mean6SEM. The dashed line indicates the starting inocula. *, p,0.05.
doi:10.1371/journal.pone.0007499.g004
Monoester/Ether Kill S. aureus
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production independent of growth inhibition, while DDG
inhibition of toxin production was dependent on bacterial growth
inhibition.
Mammalian cell toxicity
Since GML and DDG are most likely to be utilized in topical
applications, they will be in contact with epithelial cells. Therefore,
we determined the toxicity (median lethal dose, LD50) of GML
and DDG to immortalized human vaginal epithelial cells (HVECs)
using an assay to measure the membrane integrity (lactate
dehydrogenase [LDH] release) following 6 h incubations. The
LD50 of GML for a monolayer of confluent HVECs was 83 mg/ml
(95% confidence interval [CI]: 69–99 mg/ml), while the LD50 of
DDG for HVECs was 50 mg/ml (95% CI: 43–62 mg/ml) (Fig. 5).
These results indicated that DDG was statistically more toxic to
HVECs than GML. However, since the LD50 concentrations of
DDG were lower than its bacterial growth inhibition concentra-
tions in vitro, the compound may still be useful as an
antistaphylococcal agent.
In vivo rabbit Wiffle ball infection model
Both GML and DDG demonstrated in vitro potential as topical
anti-staphylococcal agents, thus their efficacy in vivo was evaluated
using a rabbit Wiffle ball infection model with compound (1 mg/
ml, every-other-day) injected directly into the site of infection [see
Materials and Methods]. This model is a model for toxic shock
syndrome (TSS) as the bacteria are localized in the Wiffle ball both
in suspension and as biofilms formed along the Wiffle ball surface;
however, superantigens penetrate the Wiffle ball encapsulation
tissue into blood circulation to cause systemic effects, including
TSS [26,27]. The survival curves for these experiments are shown
in Fig. 6A. All rabbits in the control group (N=5) died by day 4 (3
on day 2 and 2 on day 4) following inoculation of the Wiffle balls
with S. aureus (MN8) 3610
8 CFU/ml. Two of 5 rabbits in DDG
group and 4 of 5 rabbits in GML group were alive by the end of
the 7 day study. One rabbit in DDG group died on day 2, 1 on
day 4, and 1 on day 7; one rabbit in GML group died on day 2.
The survival of rabbits receiving GML (4/5) was statistically better
than the control (0/5) group (p,0.05, Fisher exact).
The Wiffle ball infection model provides the opportunity to
study the interactions among bacteria, host innate immune
responses, and therapeutic compounds by taking repeated samples
at the infection site over time. We had difficulty obtaining fluids
from Wiffle balls in two rabbits (one of the rabbits in GML and
one in DDG group).Thus, the sample analyses, including bacterial
counts, TNF-a (as a biomarker for TSS), and TSST-1 levels, were
based on available sample points. All Wiffle ball sample fluids
uniformly contained S. aureus, but Pasteurella multocida, was
recovered from a sample taken on day 2 of a rabbit in the DDG
group. That rabbit died at day 4.
One day after initial dosing, bacterial counts in the DDG
treatment group were 0.65 and 1 log lower than those in the GML
treatment and the control groups, respectively (Fig. 6B). However,
in spite of the repeated dosing, bacterial counts in DDG group
increased over time. In contrast, GML suppressed bacterial
growth throughout the 7 day study period. Neither compound
was able to achieve .3 log reduction in bacterial load within the
Wiffle ball at the concentration tested.
TSST-1 concentrations within the Wiffle ball cavities of GML
and DDG treated rabbits were lower than the control rabbits
(Fig. 6C). On day 2, TSST-1 was significantly inhibited by 60%
and 66% of the control rabbits for GML and DDG, respectively
(p,0.001, both treatments). On day 7, TSST-1 in the GML group
remained significantly lower than TSST-1 in control rabbits on
day 2 (58% reduction, p,0.05), while the level in DDG group was
not significantly lower than controls on day 2 (22% reduction).
Baseline TNF-a levels in the Wiffle ball fluids of all rabbits were
below the lower limit of detection (200 pg/ml) prior to infection
(Fig. 6D). One day after bacterial challenge, rabbits treated with
GML showed significantly lower concentrations of TNF-a in the
Wiffle ball cavities than rabbits in control and DDG treatment
groups: TNF-a average concentrations increased to 32.8 ng/ml
(range: 11.6–61.9 ng/ml), 7.9 ng/ml (range: 1.8–17.7 ng/ml), and
18.6 ng/ml (range: 3.1–95.9 ng/ml) for control, GML, and DDG
groups, respectively. TNF-a concentrations of rabbits in the GML
group remained low throughout the period of study (4.1 ng/ml;
range: 3.0–5.5 ng/ml). On the other hand, there was wide
variation in TNF-a in the DDG group. TNF-a in one rabbit
decreased from 26.9 ng/ml on day 1 to 14.7 ng/ml on day 7, but
other rabbits in this group had increasing TNF-a levels throughout
the experiment. Overall, there is no strong evidence indicating
DDG’s ability to modulate innate immune responses.
Discussion
TSS is a serious complication of S. aureus infection, and the
superantigen, TSST-1, is responsible for nearly all menstrual TSS
cases and at least half of non-menstrual cases [28]. Many
surfactants, including fatty acids linked through ester, ether,
amide, or amine bonds, appear to inhibit S. aureus growth and
toxin production [20]. However, fatty acid esters and amides are
susceptible to S. aureus enzyme degradation, and amines are
irritable to mucous membranes [29]. Therefore, fatty acid ethers
were considered to be better candidates as topical anti-staphylo-
coccal agents. Lauric acid (a 12 carbon-containing fatty acid) was
determined to be the most potent saturated fatty acid when C8 to
C18 -containing fatty acids were tested against gram-positive
Figure 5. Cytotoxicity of GML and DDG to Human Vaginal
Epithelial Cells (HVECs). HVECs were exposed to GML (&) and DDG
(m) for 6 h. Cytotoxicity was accessed by measuring the release of LDH.
Error bars are SEM. The dashed line indicates median cell survival (LD50).
Symbols:&, GML; m, DDG.
doi:10.1371/journal.pone.0007499.g005
Monoester/Ether Kill S. aureus
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potential for being incorporated into tampons to reduce risk of
TSS [18]. However, similar to other fatty acid esters, GML is
susceptible to S. aureus lipase degradation [13]. DDG, the
corresponding ether to GML, was therefore compared to GML
as an anti-staphylococcal candidate to reduce the risk of TSS. The
studies presented in this manuscript determined that GML and
DDG inhibit S. aureus growth and toxin production, although by
apparent different modes of action. In addition, a difference in
strain (clonal type) specific susceptibility to both GML and DDG
was observed. Overall, the studies indicated that GML is a
potentially better anti-staphylococcal agent than DDG for its
ability to inhibit exoprotein production regardless of effects on
bacterial growth, to reduce mortality in the rabbit Wiffle ball
infection model, and to cause less cytotoxicity to epithelial cells
than DDG.
A range of minimum inhibitory concentrations (MICs) for GML
against S. aureus have been reported. The MICs of GML against 29
strains of S. aureus in a complex medium were reported to be
between 10 to 20 mg/ml with 10
3 to 10
4 CFU/ml inocula [31].
Kabara and colleagues reported the MIC of GML against S. aureus
was 25 mg/ml with approximate 10
7 CFU/ml inocula in trypticase
soy broth [30]. Preuss et al. reported 63 mg/ml with approximate
10
5 to 10
6 CFU/mL inocula in nutrient broth [32]. Kelsey and
colleagues reported the MIC of GML against three strains of S.
aureus was 25–50 mg/ml [33]. The variability in MIC is potentially
due to culture conditions, inoculum size, and the S. aureus strains
tested [31]. By testing the compounds against a large collection of
clinical relevant strains, we confirmed that there are differences in
sensitivity to GML among bacterial strains, even within the same
clonal type. The differences in GML sensitivity may not be solely
explained by different levels of lipase produced by the strains since
the differences among S. aureus clonal types can also be observed in
the DDG group, which is not degraded by S. aureus lipase. We also
observed that USA400 strains do not produce more lipase than
USA200 strains (data not shown), despite being more resistant to
the compounds. The mechanism(s) behind the differences among
S. aureus clonal types in response to DDG and GML may be
related to cell surface hydrophobicity [34], however, this
hypothesis will need to be investigated in future studies.
Figure 6. Antistaphylococcal effects of GML and DDG in a rabbit Wiffle ball infection model. Rabbits (n=5 in each group) were infected
with 3610
8 CFU/ml S. aureus MN8, and compounds (final concentration 1 mg/ml) were instilled into the Wiffle balls every-other-day and rabbits
monitored up to 7 days. Survival of the rabbits (A), bacterial counts (B), TSST-1 production (C), and TNF-a levels (D) in the Wiffle balls. TSST-1
presented as percent of day 2 TSST-1 concentrations of the control rabbits (GML, close bars; DDG, open bars). Error bars are SEM. Symbols: #, control;
&, GML; m, DDG; *, p,0.05.
doi:10.1371/journal.pone.0007499.g006
Monoester/Ether Kill S. aureus
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aureus differently. Glycerol esters are commonly found in bacterial
membranes, and cells have mechanisms to maintain membrane
integrity in their presence. This is likely to occur also in the
presence of GML. In contrast, glycerol monoethers are uncom-
mon in bacterial membranes, and thus, the bacteria may be
expected to have greater difficulty in maintenance of membrane
integrity in the presence of DDG. As noted in our studies, GML
antimicrobial effects were dose dependent and required higher
concentrations for bactericidal activity, while DDG was predom-
inantly bacteriostatic, but active at lower concentrations than
GML. Similar mechanisms may also explain the differences
between GML and DDG on toxin inhibition. GML blocks toxin
induction by interfering with bacterial signal transduction on
bacterial cell membranes [14]. In our study, GML (25–50 mg/ml)
was able to inhibit TSST-1 production independent of S. aureus
growth inhibition properties, which is in agreement with
previously described results by Schlievert et al. (20 mg/ml) [15],
and Holland et al. (17 mg/ml) [31]. DDG was also reported to
inhibit TSST-1 production by McNamara and colleagues [20].
However, our results suggest that DDG, and likely other glycerol
monoethers, inhibition of toxin production is dependent on
bacterial growth inhibition, which is different from that of GML.
GML has a good safety profile on skin and mucosal surfaces.
The compound was considered to have negative ocular irritation
and have a LD50 of .20 g/kg for rats when dosed orally for 10
weeks [35]. In fact, GML (5% gel) was safe for chronic vaginal
administration in monkeys over a 6 month test period [17]. In
unpublished studies with year-long passage of S. aureus MN8 on
sub-growth-inhibitory concentrations of GML, we observed no
increase in resistance to GML’s antimicrobial and anti-exotoxin
effects. On the other hand, the safety of DDG in vivo has not been
well studied. In one study, mice given 1 g/kg of DDG orally per
day over 4 weeks indicated no signs of toxicity, and DDG was
quickly absorbed and eliminated into urine [36]. Since increased
doses of DDG do not enhance bacterial growth inhibition in our
study, and DDG may be more irritable to mucosal surfaces than
GML, minimal effective dose of DDG should be used.
GML has been reported to stabilize the membrane of
eukaryotic cells, modulate the production of pro-inflammatory
cytokines and thereby prevent the toxicity of bacterial exotoxins
on eukaryotic cells [16]. We have previously suggested the benefits
of GML as a dual-acting anti-infective, 1) with effects on the
microbes to prevent growth and/or exotoxin production, and 2)
with anti-inflammatory and membrane stabilizing effects on the
host epithelial cells, which reduces the disruption in the mucosal
permeability barriers caused by induction of pro-inflammatory
cytokines and chemokines following infection [19]. This latter anti-
inflammatory and membrane stabilizing property, although
counterintuitive, may be equally important or more important
than the antimicrobial effect. We reported recently that a GML
(5%) containing gel prevented SIV transmission across monkey
cervical and vaginal mucosa, despite mucosal surface GML
concentrations being below virucidal concentrations [19]. Addi-
tionally, histological studies demonstrated an inhibitory effect on
innate immunity. In our study, GML also decreased local pro-
inflammatory cytokine production (as measured by TNF-a) despite
bacterial densities of approximately 1610
7 CFU/ml over 7 days.
Production of TSST-1 is induced by elevated oxygen and
carbon dioxide levels, neutral pH, presence of proteins, and 37uC
[37]. Introduction of oxygen into the typically anaerobic vaginal
environment may account for the tampon association with TSS
[38,39]. Although abscesses are typically perceived to be
anaerobic, Todd and colleagues demonstrated that S. aureus
abscesses are aerobic, and appear to provide TSST-1 stimulating
environmental conditions, similar to those occurring vaginally in
the presence of tampons [40]. The Wiffle ball infection model as
used in this study has aspects of both types of S. aureus infections
included in an aerobic encapsulated abscess, which has internal
surfaces similar to the vaginal mucosa. As bacteria were
encapsulated in the Wiffle ball, the model provided an ideal
environment for real-time monitoring of the interactions among
the host innate immune response, bacteria, and treatments (DDG
and GML) at the infection site.
Based on the collective results of this study, GML is proposed as
more effective anti-staphylococcal topical anti-infective candidate
than DDG, despite its potential degradation by S. aureus lipase.
Materials and Methods
S. aureus isolates
Fifty-four clinical isolates were tested to assess the ability of
GML versus DDG to inhibit the growth of S. aureus. These
included 10 menstrual vaginal TSST-1
+ MSSA isolates within the
pulsed-field gel electrophoresis (PFGE) type USA200 as defined by
the CDC [41]. These isolates were from TSS patients across the
United States. Ten TSST-1
+ MRSA isolates were included within
PFGE type USA200, and all of these isolates were from
Minnesota, with 6 from patients with TSS. Five isolates were
USA400 MRSA, and 5 isolates were USA400 MSSA. All USA400
isolates were from patients with necrotizing pneumonia, purpura
fulminans, or non-menstrual TSS [42]. Three of the USA400
MRSA and three of the USA400-related MSSA isolates made the
superantigen staphylococcal enterotoxin C (SEC), and two in each
group made SEB. All ten isolates were positive for Panton-
Valentine leukocidin (PVL). Four isolates were categorized as
USA300 MRSA and were positive for the superantigen entero-
toxin-like Q and made PVL [41]. Since GML and DDG are likely
to be used topically, S. aureus derived from both skin and mucous
membranes were also evaluated. Vaginal isolates (N=10) were
obtained from healthy women during menstruation, and 10 skin
strains were obtained from patients with atopic dermatitis. These
20 isolates were not further characterized with respect to exotoxin
production or methicillin susceptibility. Collectively, these 54
clinical isolates were isolated from 1995 to 2007 and are
maintained in the Schlievert and Peterson laboratories in the
lyophilized state as low passage cultures.
S. aureus MN8 is a USA200 MSSA clinical isolate whose growth
and exotoxin responses to GML have been reported previously
[14,15]. Therefore, this strain was chosen to evaluate exotoxin
inhibitory ability of the compounds and used in the rabbit Wiffle
ball infection study.
Antimicrobial compounds
DDG (racemic 1-O-dodecylglycerol; CAS registry number:
1561-07-5; 3-(dodecyloxy)propane-1,2-diol; Alexis Corporation,
La ¨ufeltinger, Switzerland), and glycerol monolaurate (GML)
(Monomuls 90-L12; CAS registry number: 142-18-7; 2,3-dihy-
droxypropyl dodecanoate; Cognis, Cincinnati, Ohio) were pre-
pared as high concentration stocks. GML was dissolved in ethanol,
and DDG was dissolved in dimethyl sulfoxide (DMSO), as
recommended by the manufacturers.
Determination of compound degradation by bacterial
lipase
Overnight S. aureus (MN8) culture supernates (20 ml) were
filtered to remove bacteria and placed into wells on agarose slides
incorporated with either GML or DDG (500 mg/ml) and
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assessed visually by measuring zone of clearing. The method for
preparing these slides was adapted from Schlievert et al. [15].
Culture conditions
Bacteria were cultured overnight in Todd-Hewitt (TH) Bacto
broth (Becton Dickinson and Company, Sparks, MD) at 37uC with
200 revolutions per minute (RPM) shaking. Experiments were
performed with approximate starting inoculum of 1610
7 colony-
forming units (CFU)/ml with various concentrations of GML and
DDG in 1 ml of TH broth. Samples (50 ml) were serially diluted
with phosphate buffered saline (PBS; Cellgro-Mediatech Inc.,
Herndon, VA), and spirally plated onto sheep blood agar (Becton
Dickinson). Plates were incubated at 37uC overnight and CFU
counted using aCOLyte Supercount computer software (Microbi-
ology International, Frederick, Maryland). The lower limit of
accuracy was 400 CFU/ml, approximately 2.6 log10 CFU/ml. For
S. aureus MN8 experiments (6 h and 24 h), an additional 300 mlo f
samples were collected and frozen for TSST-1 quantification.
Bactericidal activity was defined as a 99.9% (3-log10 reduction in
CFU/ml) reduction in bacterial density at 18–24 h compared to
the initial inoculum. The term bacteriostatic was used when
bacterial growth compared to the initial inoculum was either not
observed or reduced by less than 99.9% [43].
TSST-1 Western blotting
Proteins in the 300 ml bacterial culture supernates were
concentrated by precipitation with 4 volumes of 100% ethanol
and re-suspended in 60 ml of sterile distilled water. Rabbit Wiffle
ball supernate samples were not concentrated. For Western
blotting, samples [1:1 mixed with Laemmli sample buffer (Bio-
Rad Laboratory, Hercules, CA)] were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE,
12% acrylamide) [44]. After transfer to polyvinylidene fluoride
membranes (Bio-Rad), the membranes were sequentially incubat-
ed with primary anti-TSST-1 (Toxin Technology. Inc., Sarasota,
FL), secondary anti-rabbit IgG-alkaline phosphatase (Sigma-
Aldrich), and 5-bromo 4-chloro 3-indolyl phosphate/nitroblue
tetrazolium (Sigma-Aldrich) for development [45]. The relative
band density was determined with ImageJ (version 1.40 g; http://
rsb.info.nih.gov/ij/).
Cytotoxicity of the compounds to human vaginal cells
Immortalized human vaginal epithelial cells (ATCC CRL-2616)
were used to determine mammalian cell cytotoxicity of GML and
DDG. The cells were maintained in Keratinocyte-Serum Free
medium (KSFM, GIBCO-BRL, Grand Island, NY), supplement-
ed with recommended supplements and antibiotics/antifungal
(100 IU/ml penicillin, 100 mg/l streptomycin, and 2.5 mg/ml
Fungizone). Cells were seeded into 96-well plates and grown to
confluency. Cells were changed to antibiotic/antifungal-free
KSFM the day before experimentation. Cells were co-incubated
with compounds for 6 h at 37uC in a humidified incubator with
7% CO2. CytoTox-One homogenous membrane integrity assay
(Promega) was used to measure the release of lactate dehydroge-
nase (LDH) from damaged cells as an indicator of membrane
integrity. Assays were performed according to the manufacturer’s
instructions. Absorbances at 560 nm (excitation) and 590 nm
(emission) wavelengths were measured by SpectraMax M2
microplate reader (Molecular Devices, Sunnyvale, CA). All
experiments were performed in triplicate. Median lethal doses
(LD50) of the compounds were the intercepts of 50% cell survival
and the regression line of the two points adjacent to the values.
Rabbit Wiffle ball infection model
Ethics statement: All animal experiments were performed
in accordance with protocols approved by the University of
Minnesota Institutional Animal Care and Use Committee
(IACUC). The rabbit Wiffle ball infection model has been
previously described [27,46]. Briefly, golf-ball-sized Wiffle balls
were implanted subcutaneously in the flanks of Dutch-belted
rabbits (either sex, 1.5 to 2.5 kg). The animals were allowed to
recover for 6–8 weeks. On day 0 of experimentation, the animals
(n=5) received 0.3 ml of 100 mg/ml GML or DDG (or solvent
control) by injection directly into the Wiffle ball (final concentra-
tion of 1 mg/ml in the 30 ml Wiffle ball). A 1 mg/ml (0.1%) final
concentration for DDG and GML was chosen and hypothesized
to be non-toxic and efficacious as we previously determined that a
GML (5%) containing gel inserted vaginally every day in monkeys
for 6 months was not toxic [17]; and initial in vitro results
indicated this concentration of GML and DDG would be
bactericidal against S. aureus and inhibit TSST-1 production.
The same treatments were administered every other day (days 2, 4,
and 6). Overnight S. aureus MN8 cultures were grown in TH broth,
washed once with PBS, and re-suspended to the desired
concentration in PBS. Immediately after injecting the compounds,
1610
10 CFU S. aureus MN8 (in a volume of 1.0 ml) was injected
into each animal’s Wiffle ball (30 ml), bringing the local
concentration to approximately 3610
8 CFU/ml. Animals were
monitored daily for signs of TSS, including fever (with use of rectal
thermometers), diarrhea, weight loss, and moribundity (as an
indication of imminent death). A small volume of fluid (0.3 ml) was
drawn from each Wiffle ball daily for bacterial counts, TSST-1
measurement, and TNF-a determination. Animals were eutha-
nized on day 7.
Tumor necrosis factor a (TNF-a) ELISA
TNF-a was used as a biomarker of inflammation at the
infection site. Purified recombinant rabbit TNF-a, capture
antibody, primary detection antibody (goat anti-rabbit TNF-a),
secondary anti-rabbit antibody (biotin mouse anti-rabbit TNF-a),
and assay reagents were commercially available from Becton
Dickinson. Rabbit Wiffle ball fluids were diluted a minimum
of 1:2 with assay buffer to eliminate viscosity and nonspecific
effects. Lower limit of detection of this assay was approximately
200 pg/ml.
Statistical methods
Paired t-tests were performed to compare the differences in
bacterial densities between GML and DDG (50 and 100 mg/ml)
against the 54 clinical S. aureus isolates. Un-paired t-tests were used
to compare the susceptibility of MRSA and MSSA. Total S. aureus
CFU/ml and TSST-1 levels among groups were compared using
one-way analysis of variance (ANOVA) with Bonferroni method to
adjust p values for multiple comparisons. Fisher’s exact test was
used to compare rabbit survival between treatment groups. A
p#0.05 was considered statistically significant. Computations and
graphing were performed using Prism version 5 (GraphPad
Software, Inc. La Jolla, CA).
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